A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Inclusion Criteria: * Healthy male and female subjects as defined in the protocol * Subjects who weigh \>50 kg at Screening Exclusion Criteria: * History of any illness or condition that might confound the results of the study or pose an additional risk to the subject upon administration of study drug - Positive for hepatitis B,C, or HIV * Standard 12-lead ECG demonstrating QTc \>450 msec for male subjects and \>480 msec for female subjects at the Screening Visit * Abnormal renal function as defined in the protocol at Screening * Forced expiratory volume in 1 second (FEV1) \<80% predicted at the Screening Visit * Blood donation (of approximately 1 pint \[500 mL\] or more) within 56 days before the first dose of study drug * Treatment with an investigational drug or device within 30 days or 5 half-lives preceding the first dose of study drug